GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Oncology/LLMs Improve Accuracy and Completeness of Cancer Pathology Summaries | JCO Clinical Cancer Informatics

LLMs Improve Accuracy and Completeness of Cancer Pathology Summaries | JCO Clinical Cancer Informatics

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated April 1, 2026

Quick Answer

Introduction Modern oncology care depends on rapid interpretation of increasingly complex pathology reports that integrate histopathology, immunohistochemistry and molecular profiling. Synthesizing these data into concise, clinically usable summaries is time-intensive and cognitively demanding, creating workflow burden and increasing the risk of omission in busy oncology practice.


Introduction

Modern oncology care depends on rapid interpretation of increasingly complex pathology reports that integrate histopathology, immunohistochemistry and molecular profiling. Synthesizing these data into concise, clinically usable summaries is time-intensive and cognitively demanding, creating workflow burden and increasing the risk of omission in busy oncology practice.

Problem Statement

Conventional physician-authored pathology summaries are often efficient but may incompletely capture key diagnostic and genomic information, particularly as molecular testing becomes more complex and voluminous. Large language models (LLMs) offer a potential solution, but their clinical reliability, completeness and safety in summarizing oncology pathology reports require careful evaluation before integration into routine practice.

Summary

This study demonstrates that open-source LLMs can generate clinically useful summaries of complex cancer pathology reports with greater completeness than physician-authored summaries while maintaining comparable correctness. Across 94 thoracic oncology cases, most LLMs outperformed physician summaries on objective measures of fidelity and consistently captured more complete clinicopathologic and genomic information, particularly molecular findings that were frequently omitted in routine documentation. Importantly, top-performing models maintained strong factual accuracy and low rates of clinically meaningful error, suggesting that LLM-assisted summarization can reduce documentation burden without compromising clinical usability. Performance, however, was model dependent: newer systems such as DeepSeek and Llama 3.1/3.2 performed reliably, whereas older or shorter-context models were more prone to omissions, unusable outputs and clinically relevant errors. The study highlights a key practical advantage of LLMs in oncology workflows—the ability to standardize and scale synthesis of increasingly complex pathology and genomic data—while also emphasizing the need for model selection, human oversight and task-specific validation. These findings support LLM-assisted pathology summarization as a promising workflow tool to improve documentation efficiency, reduce cognitive burden and enhance clinical information accessibility in cancer care.

Related Q&A

KRAS ctDNA Predicts Outcomes After Neoadjuvant Therapy in PDAC: Annals of Surgery | July 2026

Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...

Low-Dose Aspirin for Lynch Syndrome: Lancet | July 2026

Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...

4-Year Benefit of Durvalumab in BTC: JAMA Oncol | July 2026

Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...

The First Standardized PET Response Framework for Neuroendocrine Tumors: The Lancet Oncology | July 2026

Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...

Staging Laparoscopy in Gastric Cancer: Annals of Surgical Oncology | July 2026

Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...

Celecoxib Boosts Neoadjuvant Immunotherapy in dMMR/MSI-H CRC : Lancet Oncol | Jul 2026

Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer